MARKET

ZLAB

ZLAB

Zai Lab
NASDAQ

Real-time Quotes | Nasdaq Last Sale

76.62
+0.59
+0.78%
Closed 16:00 09/23 EDT
OPEN
75.89
PREV CLOSE
76.03
HIGH
76.81
LOW
74.94
VOLUME
339.42K
TURNOVER
--
52 WEEK HIGH
89.48
52 WEEK LOW
29.43
MARKET CAP
5.78B
P/E (TTM)
-22.5240
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Zai Lab Announces Pricing of Hong Kong Secondary Listing
SHANGHAI and SAN FRANCISCO, Sept. 22, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ: ZLAB), an innovative commercial stage biopharmaceutical company, today announced the pricing of the Hong Kong secondary listing (the “Hong Kong Secondary Listing”) of 10,564,050 new ordinary
GlobeNewswire · 1d ago
Zai Lab prices Hong Kong listing at HK$562
Zai Lab Limited (ZLAB) prices Hong Kong secondary listing of 10.56M ordinary shares at HK$562.00 per share for gross proceeds of HK$5.94B.Based on the ratio of one ordinary shares to ADS,
Seekingalpha · 1d ago
Zai Lab Prices 10,564,050 Share Hong Kong Secondary Listing At HK$562.00/Share
SHANGHAI and SAN FRANCISCO, Sept. 22, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited ("Zai Lab" or the "Company") (NASDAQ:ZLAB), an innovative commercial stage biopharmaceutical company, today announced the
Benzinga · 1d ago
ZTO Express Raises $1.27 Billion in Hong Kong Listing
(Bloomberg) -- Chinese courier service giant ZTO Express Cayman Inc. and drug developer Zai Lab Ltd. raised a combined HK$15.7 billion ($2 billion) in their second listings in Hong Kong, according to people familiar with the matter, adding to the flurry of share sales in the financial hub by U.S.-traded
Bloomberg · 1d ago
Week In Review: Zai Lab To Raise Up To $845 Million In Hong Kong IPO
Zai Lab of Shanghai is conducting a Hong Kong IPO that is expected to raise up to $845 million, offering 12.3% of the company's expanded number of shares.Tianjin JuveStar Biotech, a Fosun Pharma affiliate, acquired Greater China rights to an aesthetic product from Israel's Raziel Therapeutics in a $74 million agreement.Shanghai's I-Mab and MorphoSys AG of Munich announced they have permission to start US trials of an anti-C5aR1 antibody in patients with advanced solid tumors.
Seekingalpha · 2d ago
Tracking Ron Baron's BAMCO Portfolio - Q2 2020 Update
BAMCO’s 13F portfolio value increased from $20.41B to $27.66B this quarter.Ron Baron added ZoomInfo Tech and increased Zillow Group during the quarter.Their top five positions are at ~22% of the overall portfolio.
Seekingalpha · 2d ago
Zai Lab' niraparib shows PFS benefit, compared to placebo
Zai Lab ([[ZLAB]] -8.2%) announced detailed results from the ZEJULA NORA (Phase 3) study, as a maintenance therapy in Chinese patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in
Seekingalpha · 2d ago
Zai Lab Announced Saturday Phase 3 Nora Data of Zejula Demonstrate Significant Pfs Benefit, Regardless of Biomarker Status, With an Improved Safety Profile When Given With Individualized Starting Dose Regimen in Chinese Women With Platinum-sensitive Recurrent Ovarian Cancer
Zai Lab Limited (NASDAQ: ZLAB) announced Saturday detailed positive results from the NORA study, the Phase 3 randomized, double-blind, placebo-controlled study of ZEJULA (niraparib) as a maintenance therapy in Chinese patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer (collectively termed
Benzinga · 3d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ZLAB. Analyze the recent business situations of Zai Lab through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ZLAB stock price target is 100.08 with a high estimate of 111.00 and a low estimate of 90.00.
EPS
Institutional Holdings
Institutions: 189
Institutional Holdings: 50.62M
% Owned: 67.16%
Shares Outstanding: 75.38M
TypeInstitutionsShares
Increased
70
5.34M
New
51
-139.42K
Decreased
36
3.05M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.78%
Pharmaceuticals & Medical Research
-1.14%
Key Executives
Chairman/Chief Executive Officer/Co-Founder/Director
Du Ying
President/Chief Operating Officer/Director
Fu Tao
Chief Financial Officer
Billy Cho
Executive Vice President
Ning Xu
Executive Vice President
James Yan
Senior Vice President
Jonathan Wang
Chief Scientific Officer
Valeria Fantin
Other
F. Ty Edmondson
Other
William Liang
Other
Harald Reinhart
Other
Hei Yongjiang
Director
Nisa Leung
Director
Peter Wirth
Independent Director
John Diekman
Independent Director
Chen Kai-Xian
Independent Director
William Lis
Independent Director
Leon Moulder
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ZLAB
Zai Lab Ltd is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include three drug candidates with greater China rights and three drug candidates with global rights. The greater China rights drug candidates include Niraparib (ZL-2306), Omadacycline (ZL-2401) and ZL-2301. The global rights drug candidates include Fugan (ZL-3101), ZL-2302 and ZL-1101.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Zai Lab Ltd stock information, including NASDAQ:ZLAB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZLAB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ZLAB stock methods without spending real money on the virtual paper trading platform.